Presented in part at the Annual Scientific Meeting of the Royal College of Pathologisls of Australasia, Hobart, October 1988.
Vimentin—a new prognostic parameter in breast carcinoma?†
Article first published online: 15 JUN 2005
Copyright © 1989 John Wiley & Sons, Ltd.
The Journal of Pathology
Volume 158, Issue 2, pages 107–114, June 1989
How to Cite
Raymond, W. A. and Leong, A. S.-Y. (1989), Vimentin—a new prognostic parameter in breast carcinoma?. J. Pathol., 158: 107–114. doi: 10.1002/path.1711580205
- Issue published online: 15 JUN 2005
- Article first published online: 15 JUN 2005
- Manuscript Accepted: 24 NOV 1988
- Manuscript Received: 5 OCT 1988
- monoclonal antibody;
- growth fraction;
- intermediate filaments;
- oestrogen receptors;
- bistological tumour grade
This report describes a positive relationship between vimentin expression in infiltrating ductal breast carcinoma, and high tumour growth fraction. Vimentin expression is potentially a predictor of aggressive behaviour, and such carcinomas may benefit from early adjuvant therapy.
Eighty-four malignant breast neoplasms were stained with monoclonal anti-vimentin and anti-cytokeratin antibodies. The tumour growth fractions were determined by immunostaming cryostat sections with the Ki-67 antibody. Seven (9.2 per cent) of 76 infiltrating ductal carcinomas co-expressed cytokeratin and vimentin intermediate filaments in more than 50 per cent of neoplastic cells. In each case, the corresponding Ki-67 count was ≥40 percent, significantly higher than the mean growth fraction for all tumours examined (P<0.0001). Vimentin immunoreactivity was also positively related to the histological grade of the ductal carcinomas (P<0.002) and inversely related to tumour ER count (P<0.0002) and patient age (P<0.01). No relationship was observed between vimentin positivity and either the presence of axillary nodal metastases or primary tumour size.